Mental Health

AI Denial Machine

The concept lived in board glosses; now the evidence supports a thread: a federal court ordered broad discovery into UHC's algorithmic claims-denial process (04-23), Minnesota banned AI-alone denials, Congress is fighting CMS's WISeR AI prior-auth pilot, an OIG report hit MA denial rates, and Elevance's BH "ghost network" class action was allowed to proceed (04-01) — the network-adequacy strand. Track: the UHC discovery outputs, WISeR's fate, state AI-denial bans spreading, and Humana's nH Predict suit (quiet, distinct docket).

STATUS · OPEN OPENED · 2026-07-28 LAST SEEN · 2026-07-28

unitedhealth-group cigna humana elevance-health

This week's evidence

UnitedHealth's two public faces, same quarter: CEO on Q2 call — AI runs "virtually everything," 96% first-pass prior-auth approval — while nH Predict discovery proceeds over an alleged ~90% appeal-reversal rate. Both numbers describe the same adjudication machine; watch for either cited against the other in court. (PYMNTS, 07-15 call, surfaced today) 2026-07-28 · NEW

2026-07-15 — UnitedHealth self-reports the practice under discovery

CEO Stephen Hemsley told Q2 2026 earnings-call investors “virtually everything” UHC does now runs through AI, including a 96% first-pass prior-authorization approval rate and a committed 30% cut to prior-auth volume by year-end — the identical claims-automation UHC is under federal discovery over (nH Predict/naviHealth). Optum Rx separately cut AI-driven Rx approval times from 8+ hours to under 30 seconds. The company is leaning further into the exact practice its own litigation disputes, in public, on the record. (PYMNTS) ⟨daily 2026-07-28⟩

2026 — The evidence base at opening ⟨crawl 2026-07-28⟩

04-23 — federal court ordered broad discovery into UnitedHealthcare’s algorithmic claims-denial process — the strongest legal beachhead yet.
04-01 — Elevance’s BH “ghost network” class action allowed to proceed (inaccurate provider directories — the network-adequacy strand).
Minnesota banned AI-alone denials; Congress fighting CMS’s WISeR AI prior-auth pilot; OIG report on MA denial rates — the regulatory front widened through H1.
Background: Cigna’s PXDX (ProPublica 2023) still defines the genre; Humana’s nH Predict suit (Barrows) is the quiet, distinct docket.